Allergan To Slash Jobs In Preparation Of Generic Competition For Top-Selling Drugs
The biggest generic threat to Allergan is to its eye treatment drug Restasis. The company has taken various steps to shield Restasis from competition, notably selling its patents to an Indian tribe in New York state to avoid a U.S. Patent and Trademark Office hearing on the validity of the drug’s patents.